Research graph
References from CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas. Local targets link to admitted publications; unresolved targets remain external evidence.
Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network
10.1038/bjc.2015.94 · 2015 · External reference
Marginal-zone lymphomas
10.1056/nejmra2102568 · 2022 · External reference
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
10.1182/blood-2016-01-643569 · 2016 · External reference
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria
10.1038/sj.leu.2405068 · 2008 · External reference
Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?
10.1097/pas.0b013e318271243d · 2012 · External reference
Clinicopathologic features of CD5-positive nodal marginal zone lymphoma
10.1309/ajcpemvxes72duif · 2013 · External reference
Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production
10.1182/blood-2002-05-1525 · 2002 · External reference
De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients
10.1182/blood.v99.3.815 · 2002 · External reference
Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH
10.1111/ejh.12847 · 2017 · External reference
De novo CD5(+) diffuse large B-cell lymphoma: biology, mechanism, and treatment advances
10.1016/j.clml.2020.05.003 · 2020 · External reference
CD5 gene signature identifies diffuse large B-cell lymphomas sensitive to Bruton's tyrosine kinase inhibition
2023 · External reference
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
10.1002/ajh.26367 · 2021 · External reference
New directions for mantle cell lymphoma in 2022
2022 · External reference
Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia
10.1056/nejmoa1513257 · 2016 · External reference
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
10.1016/s0140-6736(12)61763-2 · 2013 · External reference
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era
10.1111/bjh.14228 · 2016 · External reference
Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma
10.1007/s00277-013-1900-4 · 2014 · External reference
Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance
10.1182/blood-2018-02-833608 · 2018 · External reference
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study
10.1111/bjh.15641 · 2018 · External reference
Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma
10.1002/ajh.25707 · 2020 · External reference
Chemotherapy-free management of follicular and marginal zone lymphoma
10.2147/cmar.s267258 · 2021 · External reference
CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab
10.1080/10428194.2021.1973670 · 2022 · External reference
Competing risk regression models for epidemiologic data
10.1093/aje/kwp107 · 2009 · External reference
Tutorial in biostatistics: competing risks and multi-state models
10.1002/sim.2712 · 2007 · External reference
A proportional hazards model for the subdistribution of a competing risk
10.1080/01621459.1999.10474144 · 1999 · External reference
A MALT lymphoma prognostic index
10.1182/blood-2017-03-771915 · 2017 · External reference
Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group
10.1182/blood-2010-02-267476 · 2010 · External reference
CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases
10.3324/haematol.2009.011049 · 2010 · External reference
CD5-positive marginal zone lymphoma: clinicopathological features and survival outcomes
10.1016/j.leukres.2022.106840 · 2022 · External reference
The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment
10.1182/asheducation-2017.1.329 · 2017 · External reference
Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features
10.1158/0008-5472.can-12-1615 · 2012 · External reference
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection
10.1080/10428194.2022.2148218 · 2023 · External reference
Outcome of deferred initial therapy in mantle-cell lymphoma
10.1200/jco.2008.19.6121 · 2009 · External reference
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse
10.1038/s41408-019-0209-5 · 2019 · External reference
